SciTechDailyWelt

Gewichtsmedikamente wie Ozempic bergen unerwartete Risiken

Neue Forschungsergebnisse deuten darauf hin, dass Versprechen der GLP-1-Weglufigkeitsmedikamente wird: einem sich ndernden und manchmal intensivierten sozialen Stigma.

6. Mai 2026RedaktionLive Redaktion
Weight-Loss Drugs Like Ozempic May Come With an Unexpected Cost

Kurzfassung

Warum das wichtig ist

SciTechDailyWelt
  • Neue Forschungsergebnisse deuten darauf hin, dass Versprechen der GLP-1-Weglufigkeitsmedikamente wird: einem sich ndernden und manchmal intensivierten sozialen Stigma.
  • New research suggests that the promise of GLP-1 weight loss drugs is accompanied: shifting, and sometimes intensified, stigma.
  • GLP-1 drugs like Ozempic Wegovy have rapidly transformed weight loss from a frustrating, often futile struggle into something that, for many, finally works.

In the past few years, these medications have surged in popularity, with tens of millions of prescriptions written worldwide and an estimated 1 in 8 U.S. adults reporting they’ve tried a GLP-1 drug at some point. Celebrities, executives, and everyday patients alike have embraced them, fueling what some call a new era of obesity treatment.

But a new study from Rice University suggests that the public reaction to these medications is not simply admiration or acceptance. In some situations, people who use them may face more criticism than those who do not lose weight at all. The research, led, assistant professor of psychological sciences Rice University and published in International Journal Obesity, reveals a striking pattern of bias.

Co-authors include Sean Phelan of Mayo Clinic Janet Tomiyama of University California, Angeles. “We expected there might be some stigma around using a GLP-1,” Standen said. “But what surprised us was the extent of it.” Perceptions Weight Loss Methods In the study, participants were asked to evaluate a fictional person based on their weight history.

The individual either lost weight using

The individual either lost weight using a GLP-1 medication, lost weight through diet and exercise, or did not lose weight at all. The results showed a clear trend. People viewed those who used GLP-1 medications less favorably than those who lost weight through diet and exercise.

More strikingly, participants rated GLP-1 users more negatively than individuals who had not lost weight at all. “The GLP-1 users were socially penalized not just compared to someone who lost weight through diet and exercise,” Standen said. “They were also rated more harshly than someone who didn’t lose weight in the first place.” These findings suggest that weight-related stigma does not disappear after weight loss.

Instead, it can shift depending on how the weight loss occurs. “There’s this idea that if you lose weight, you might escape stigma,” Standen said. “But what we’re seeing is that people may face judgment at multiple points.

Gewichtsmedikamente wie Ozempic bergen unerwartete Risiken
Gewichtsmedikamente wie Ozempic bergen unerwartete Risiken

They may be judged for their

They may be judged for their weight and for how they choose to manage it.” As GLP-1 medications become more widely used, these perceptions may play a growing role. “There’s a narrative that using these medications is ‘taking the easy way out,’” Standen said. “And that belief seems to shape how people are judged.” What Happens When Weight Returns The researchers also examined what happens when people stop using GLP-1 medications.

Many discontinue them because of cost, insurance limits, or side effects, and weight regain is common.

The study found that individuals who regained weight, whether after using a GLP-1 drug or following a diet, were judged more negatively than those who lost weight and maintained it. “There’s a lot of stigma tied to weight regain in general,” Standen said. “And that doesn’t seem to depend much on how the weight was lost in the first place.” Broader Health Implications Standen emphasized that these attitudes can have real health consequences.

Weight stigma has been linked to

Weight stigma has been linked to stress, avoidance of medical care, and unhealthy coping behaviors. “If people feel judged for the choices they’re making about their health, that can influence what they’re willing to do,” she said. “It can affect whether they seek care, whether they talk openly with providers and how they manage their health overall.” This issue is especially important as GLP-1 medications continue to gain attention and use. “This is a moment where these treatments are really entering the mainstream,” Standen said. “So understanding the side of that is critical.” Rethinking Narrative Around Weight Standen’s research is part of a broader effort to encourage healthier behaviors without reinforcing stigma.

Her goal is to understand how people can make informed choices about their health without feeling judged. “There’s such a strong cultural script around weight and what a ‘healthy’ body should look like,” she said. “And those messages can get in the way of people doing what’s actually best for them.” She hopes the findings will help shift public attitudes. “Ultimately, any form of stigma related to someone’s body or their health choices is not helpful,” Standen said. “People should be able to make decisions that are right for them without fear of being judged.” Reference: “An experimental investigation of the stigmatization of weight loss and regain from GLP-1 receptor agonist use and cessation”, Sean M.

Phelan and A. Janet Tomiyama, 3 April 2026, International Journal Obesity. DOI: 10.1038/s41366-026-02061-y

Quellenprofil

Quelle und redaktionelle Angaben

Quelle
SciTechDaily
Originaltitel
Weight-Loss Drugs Like Ozempic May Come With an Unexpected Cost
Canonical
https://scitechdaily.com/weight-loss-drugs-like-ozempic-may-come-with-an-unexpected-cost/
Quell-URL
https://scitechdaily.com/weight-loss-drugs-like-ozempic-may-come-with-an-unexpected-cost/

Aehnliche Inhalte

Verwandte Themen und interne Verlinkung

Weitere Artikel aus aehnlichen Themenfeldern, damit Leser direkt im selben Kontext weiterlesen koennen.